Coen van Hasselt
Assistant professor
- Name
- Dr. J.G.C. van Hasselt
- Telephone
- +31 71 527 3266
- j.g.c.van.hasselt@lacdr.leidenuniv.nl
Coen van Hasselt is an assistant professor at the Division of Systems Biomedicine and Pharmacology, which is part of the Leiden Academic Centre for Drug Research (LACDR). I am establishing the Quantitative Pharmacology group, where we aim to develop and apply quantitative pharmacological modeling approaches (pharmacometrics) with systems biology- and bioinformatics based modeling approaches to optimize translational drug development and to support individualized drug treatment. Our group is primarily interested to study the translational and clinical pharmacology of antibiotics and antimicrobial resistance, to optimize antibiotic treatments. Besides computational expertise, we have established an experimental lab to conduct state-of-the-art translational antimicrobial PK/PD experiments. Other therapeutic areas of interest are anti-cancer drug pharmacology and adverse drug reactions. In our work we collaborate extensively with both clinicians and several experimental groups.
Coen van Hasselt is an assistant professor at the Division of Systems Biomedicine and Pharmacology, which is part of the Leiden Academic Centre for Drug Research (LACDR). I am establishing the Quantitative Pharmacology group, where we aim to develop and apply quantitative pharmacological modeling approaches (pharmacometrics) with systems biology- and bioinformatics based modeling approaches to optimize translational drug development and to support individualized drug treatment. Our group is primarily interested to study the translational and clinical pharmacology of antibiotics and antimicrobial resistance, to optimize antibiotic treatments. Besides computational expertise, we have established an experimental lab to conduct state-of-the-art translational antimicrobial PK/PD experiments. Other therapeutic areas of interest are anti-cancer drug pharmacology and adverse drug reactions. In our work we collaborate extensively with both clinicians and several experimental groups.
My PhD degree (2014) was received from the Netherlands Cancer Institute/Utrecht University, with a PhD thesis on novel integrative quantitative pharmacological modeling approaches to optimize drug treatment in oncology. I then was a postdoctoral researcher at the LACDR focusing on antibiotics PK/PD. Between 2015-2017 I was a postdoctoral research fellow at the Ravi Iyengar lab focusing on innovatvie systems pharmacology approaches, at the Icahn School of Mount Sinai, NY, USA, supported by a competetive personal Marie Curie Individual Fellowship.
Assistant professor
- Wiskunde en Natuurwetenschappen
- Leiden Academic Centre for Drug Research
- LACDR/Pharmacology
- Calizo R.C., Bhattacharya S., Hasselt J.G.C. van, Wei C., Wong J.S., Wiener R.J., Ge X., Wong N.J., Lee J.J., Cuttitta C.M., Jayaraman G., Au V.H., Janssen W., Liu T., Li H., Salem F., Jaimes E.A., Murphy B., Campbell K.N. & Azelogu E.U. (2019), Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity, Nature Communications 10: 2061.
- Centanni M., Moes D.J.A.R., Trocóniz I.F., Ciccolini J. & Hasselt J.G.C. van (2019), Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors, Clinical Pharmacokinetics 58(7): 835-857.
- Hasselt J.G.C. van & Iyengar R. (2019), Systems Pharmacology: Defining the Interactions of Drug Combinations, Annual Review of Pharmacology and Toxicology 59: 21-40.
- Saleh M.A.A.E.W., Garde E.M.W. van de & Hasselt J.G.C. van (2018), Host-response biomarkers for the diagnosis of bacterial respiratory tract infections, Clinical Chemistry and Laboratory Medicine 57(4): 442-451.
- Yin A., Yamada A., Stam W.B., Hasselt J.G.C. van & Graaf P.H. van der (2018), Quantitative systems pharmacology analysis of drug combination and scaling to humans: the interaction between noradrenaline and vasopressin in vasoconstriction, British Journal of Pharmacology 175(16): 3394-3406.
- Illamola S.M., Sherwin C.M. & Hasselt J.G.C. van (2018), Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses, Clinical Pharmacokinetics 57(10): 1217-1228.
- Ramamoorthy A., Sadler B.M., Hasselt J.G.C. van, Elassaiss J., Kasichayanula S, Edwards A.Y., Graaf P.H. van der, Zhang L & Wagner J.A. (2018), Crowdsourced Asparagus Urinary Odor Population Kinetics, CPT: Pharmacometrics & Systems Pharmacology 7(1): 34-41.
- Vries Schultink A.H.M. de, Boekhout A.H., Gietema J.A., Burylo A.M., Dorlo T.P.C., Hasselt J.G.C. van, Schellens J.H.M. & Huitema A.D.R. (2018), Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens, Journal of Pharmacokinetics and Pharmacodynamics 45(3): 431-442.
- Aulin L.B.S., Valitalo P.A., Rizk M.L., Visser S.A.G., Rao G., Graaf P.H. van der & Hasselt J.G.C. van (2018), Validation of a Model Predicting Anti-infective Lung Penetration in the Epithelial Lining Fluid of Humans, Pharmaceutical Research 35(2): 26.
- Yamamoto Y., Valitalo P.A.J., Huntjens D.R., Proost J.H., Vermeulen A., Krauwinkel W., Beukers M.W., Berg D.J. van den, Hartman R.J., Wong Y.C., Danhof M., Hasselt J.G.C. van & Lange E.C.M. de (2017), Predicting Drug Concentration-Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically-Based Pharmacokinetic Model, CPT: Pharmacometrics & Systems Pharmacology 6(11): 765–777.
- Krekels E.H.J., Hasselt J.G.C. van, Anker J.N. van den, Allegaert K., Tibboel D. & Knibbe C.A.J. (2017), Evidence-based drug treatment for special patient populations through model-based approaches, European Journal of Pharmaceutical Sciences 109(Supplement): S22-S26.
- Kohler I., Hankemeier T., Graaf P.H. van der, Knibbe C.A.J. & Hasselt J.G.C. van (2017), Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine, European Journal of Pharmaceutical Sciences 109: S15-S21.
- Goulooze S.C., Krekels E.H.J., Dijk M. van, Tibboel D., Graaf P.H. van der, Hankemeier T., Knibbe C.A.J. & Hasselt J.G.C. van (2017), Towards personalized treatment of pain using a quantitative systems pharmacology approach, European Journal of Pharmaceutical Sciences 109: S32-S38.
- Yamamoto Y., Välitalo P.A., Wong Y.C., Huntjens D.R., Proost J.H., Vermeulen A., Krauwinkel W., Beukers M.W., Kokki H., Kokki M., Danhof M., Hasselt J.G.C. van & Lange E.C.M. de (2018), Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach, European Journal of Pharmaceutical Sciences 112: 168-179.
- Nguyen T.H.T., Mouksassi M.S., Holford N., Al-Huniti N., Freedman I., Hooker A..C, John J., Karlsson M.O., Mould D.R., Pérez Ruixo J.J., Plan E.L., Savic R., Hasselt J.G.C. van, Weber B., Zhou C., Comets E. & Mentré F. (2017), Model evaluation of continuous data pharmacometric models: Metrics and graphics., CPT: Pharmacometrics & Systems Pharmacology 6(2): 87-109.
- Yamamoto Y., Välitalo P.A., Berg D.J. van den, Hartman R.J., Brink W. van den, Wong Y.C., Huntjens D.R., Proost J.H., Vermeulen A., Krauwinkel W., Bakshi S.D., Aranzana-Climent V., Marchand S., Dahyot-Fizelier C., Couet W., Danhof M., Hasselt J.G.C. van & Lange E.C.M. de (2017), A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations, Pharmaceutical Research 34(2): 333–351.
- Jacobs B.A., Deenen M.J, Pluim D, Hasselt J.G.C. van, Krähenbühl M.D., Geel R.M van, Vries N. de, Rosing H., Meulendijks D., Burylo A.M., Cats A., Beijnen J.H., Huitema A.D. & Schellens J.H. (2016), Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers, British Journal of Clinical Pharmacology 82(3): 706-716.
- Hasselt J.G. van, Rizk M.L., Lala M., Chavez-Eng C, Visser S.A., Kerbusch T., Danhof M., Rao G. & Graaf P.H. van der (2016), Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid, British Journal of Clinical Pharmacology 81: 1113–1123.
- Illamola S.M., Colom H. & Hasselt J.G. van (2016), Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies, British Journal of Clinical Pharmacology 82(3): 793-805.
- Meulensdijks D., Hasselt J.G.C. van, Huitema A.D.R., Tinteren H. van, Deenen M.J, Beijnen J.H., Cats A. & Schellens J.H.M. (2016), Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care, European Journal of Cancer 2016(54): 120-130.
- Valitalo P.A.J., Griffioen K., Rizk M., Visser S., Danhof M., Rao M., Graaf P. & Hasselt J.G.C. van (2016), Structure-based prediction of anti-infective drug concentrations in the human lung epithelial lining fluid, Pharmaceutical Research 33(4): 856-867.
- Hasselt J.G.C. van, Gupta A., Hussein Z., Beijnen J., Schellens J. & Huitema A. (2015), Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin, CPT: Pharmacometrics {&} Systems Pharmacology 4(7): 386--395.
- Yu H., Steeghs N., Kloth J.S.L., Wit D., Hasselt J.G.C. van, Erp N.P., Beijnen J.H., Schellens J.H.M., Mathijssen R.H.J. & Huitema A.D.R. (2015), Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662, British Journal of Clinical Pharmacology 79(5): 809--819.
- Hasselt J.G.C. van, Gupta A., Hussein Z., Beijnen J., Schellens J. & Huitema A. (2015), Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin, CPT: Pharmacometrics {&} Systems Pharmacology 4(7): 374--385.
- Frederix G., Severens J., Hö}vels A., Hasselt J., Hooiveld M., Neven P., Raaijmakers J. & Schellens J. (2015), Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium, European Journal of Cancer Care 24(3): 340--354.
- Hasselt J.C. & Graaf P.H. (2015), Towards integrative systems pharmacology models in oncology drug development, Drug Discovery Today: Technologies 15: 1--8.
- Hasselt J.G.C. van, Eijkelenburg N..KA., Beijnen J.H., Schellens J.H.M. & Huitema A.D.R. (2014), Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation., Pediatric Blood and Cancer 61(12): 2223--2229.
- Hasselt J.G.C. van, Schellens J.H.M., Beijnen J.H. & Huitema A.D.R. (2014), Design of informative renal impairment studies: evaluation of the impact of design stratification on bias, precision and dose adjustment error., Investigational New Drugs 32(5): 913--927.
- Hasselt J.G.C. van, Calsteren K., Heyns L., Han S., Mhallem Gziri M., Schellens J.H.M., Beijnen J.H., Huitema A.D..R & Amant F. (2014), Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel., Annals of Oncology: European society for medical oncology 25(10): 2059--2065.
- van Hasselt JGC, Allegaert K, van Calsteren K, Beijnen JH, Schellens JHM & Huitema ADR (2014), Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy, BioMed Research International 2014(Article ID 897216): 1-9DO - 10.1155/2014/897216.
- Frederix GWJ, van Hasselt JGC, Severens JL, Hovels AM, Huitema ADR, Raaijmakers JAM & Schellens JHM (2013), Development of a Framework for Cohort Simulation in Cost-Effectiveness Analyses Using a Multistep Ordinary Differential Equation Solver Algorithm in R, Medical Decision Making 33(6): 780-792.
- van Hasselt JGC, van Eijkelenburg NKA, Beijnen JH, Schellens JHM & Huitema ADR (2013), Optimizing drug development of anti-cancer drugs in children using modelling and simulation, British Journal of Clinical Pharmacology 76(1): 30-47.
- van Hasselt JGC, Gupta A, Hussein Z, Beijnen JH, Schellens JHM & Huitema ADR (2013), Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate associated neutropenia., British Journal of Clinical Pharmacology 76(6): 2878-81.
- van Hasselt JGC, van Eijkelenburg NKA, Huitema ADR, Schellens JHM & Schouten-van Meeteren AYN (2013), Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate., Antimicrobial Agents and Chemotherapy 57(6): 2878-81.
- Klumpers LE, Roy C, Ferron G, Turpault S, Poitiers F, Pinquier J, van Hasselt JGC, Zuurman L, Erwich FAS & van Gerven JMA (2013), Surinabant, a selective CB(1) antagonist, inhibits THC-induced central nervous system and heart rate effects in humans., British Journal of Clinical Pharmacology 76(1): 65-77.
- Frederix GWJ, van Hasselt JGC, Schellens JHM, Hövels AM, Raaijmakers JAM, Huitema ADR & Severens JL (2013), The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance., Pharmacoeconomics .
- Frederix G.W.J., Severens J..L, Hövels A.M., Hasselt J.G.C. van, Raaijmakers J.A.M. & Schellens J.H.M. (2013), Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer, Breast Cancer Research and Treatment 139(2): 489-495.
- Hasselt J.G.C. van, Green B. & Morrish G.A. (2012), Leveraging Physiological Data from Literature into a Pharmacokinetic Model to Support Informative Clinical Study Design in Pregnant Women., PHARMACEUTICAL RESEARCH 29(6): 1609-1617.
- Hasselt J.G.C. van, Schellens J.H.M., Mac Gillavry M.R., Beijnen J.H. & Huitema A.D.R. (2012), Model-Based Evaluation and Optimization of Cardiac Monitoring Protocols for Adjuvant Treatment of Breast Cancer with Trastuzumab, PHARMACEUTICAL RESEARCH 29(12): 3499-3511.
- Klumpers L.E., Beumer T.L., Hasselt J.G.C. van, Lipplaa A., Karger L.B., Kleinloog D., Freijer J.I., Kam M.L. de & Gerven J.M.A. van (2012), Novel Δ9-tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects, British Journal of Clinical Pharmacology 74(1): 42-53.
- Broek M.P.H. van den, Groenendaal F., Toet M.C., Straaten H.L.M. van, Hasselt J.G.C. van, Huitema A.D.R., Vries L.S. de, Egberts A.C.G. & Rademaker C.M.A. (2012), Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia : a thermopharmacological approach, Clinical Pharmacokinetics 51(10): 671-679.
- Mallaysamy S., Johnson M.G., Rao P.G.M., Rajakannan T., Bathala L., Arumugam K., Hasselt J.G.C. van & Ramakrishna D. (2012), Population pharmacokinetics of lamotrigine in Indian epileptic patients., European Journal of Clinical Pharmacology 69(1): 43-52.
- Hasselt J.G.C. van, Heuvel M.M. van den, Schellens J.H.M., Beijnen J.H., Brandsma D. & Huitema A.D.R. (2012), Severe Cannabinoid Intoxication in a Patient with Non Small Cell Lung Cancer, Journal of palliative care 28(1): 60-61.
- Hasselt J.G.C. van, Andrew M.A., Hebert M.F., Tarning J., Vicini P. & Mattison D.R. (2012), The Status of Pharmacometrics in Pregnancy: Highlights from the 3(rd) American Conference on Pharmacometrics, British Journal of Clinical Pharmacology 74(6): 932-939.
- Dumont G.J.H., Hasselt J.G.C. van, Kam M. de, Gerven J.M.A. van, Touw D.J., Buitelaar J.K. & Verkes R.J. (2011), Acute psychomotor, memory and subjective effects of MDMA and THC co-administration over time in healthy volunteers, Journal of Psychopharmacology 25(4): 478-489.
- Broek M.P.H. van den, Huitema A.D.R., Hasselt J.G.C. van, Groenendaal F., Toet M.C., Egberts T.C.G., Vries L.S. de & Rademaker C.M.A. (2011), Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures, Clinical Pharmacokinetics 50(7): 461-469.
- Liem-Moolenaar M., Boer P. de, Timmers M., Schoemaker R.C., Hasselt J.G.C. van, Schmidt S. & Gerven J.M.A. van (2011), Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects, British Journal of Clinical Pharmacology 71(6): 886-898.
- Hasselt J.G.C. van, Boekhout A.H., Beijnen J.H., Schellens J.H.M. & Huitema A.D.R. (2011), Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity, CLINICAL PHARMACOLOGY & THERAPEUTICS 90(1): 126-132.
- Krekels E.H.J., Hasselt J.G.C. van, Tibboel D., Danhof M. & Knibbe C.A.J. (2011), Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models, PHARMACEUTICAL RESEARCH 28(4): 797-811.
- Lo Y.L., Hasselt J.G.C. van, Heng S.C., Lim C.T., Lee T.C. & Charles B.G. (2010), Population pharmacokinetics of vancomycin in premature malaysian neonates: identification of predictors for dosing determination, Antimicrobial Agents and Chemotherapy 54(6): 2626-2632.
- Dumont G.J.H., Kramers C., Sweep F.C., Touw D.J., Hasselt J.G.C. van, Kam M.L. de, Gerven J.M.A. van, Buitelaar J.K. & Verkes R.J. (2009), Cannabis coadministration potentiates the effects of "ecstasy" on heart rate and temperature in humans, CLINICAL PHARMACOLOGY & THERAPEUTICS 86(2): 160-166.
- Wirtz P.W., Verschuuren J.J., Dijk J.G. van, Kam M.L. de, Schoemaker R.C., Hasselt J.G.C. van, Titulaer M.J., Tjaden U..R, Hartigh J. den & Gerven J.M.A. van (2009), Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study, Clinical Pharmacology and Therapeutics 86(1): 44-48.
- Penningmeester